AR102147A1 - Composición farmacéutica que comprende aspirina, metformina y serotonina con agente tensioactivo no iónico - Google Patents

Composición farmacéutica que comprende aspirina, metformina y serotonina con agente tensioactivo no iónico

Info

Publication number
AR102147A1
AR102147A1 ARP150103170A ARP150103170A AR102147A1 AR 102147 A1 AR102147 A1 AR 102147A1 AR P150103170 A ARP150103170 A AR P150103170A AR P150103170 A ARP150103170 A AR P150103170A AR 102147 A1 AR102147 A1 AR 102147A1
Authority
AR
Argentina
Prior art keywords
metformin
agent
pharmaceutical composition
aspirine
serotonine
Prior art date
Application number
ARP150103170A
Other languages
English (en)
Inventor
Chen Chien
Hung
Original Assignee
Als Mountain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Mountain Llc filed Critical Als Mountain Llc
Publication of AR102147A1 publication Critical patent/AR102147A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica que consiste de: (1) una cantidad terapéuticamente efectiva de un primer agente que es metformina o una sal de la misma; (2) una cantidad terapéuticamente efectiva de un segundo agente que es aspirina; (3) una cantidad terapéuticamente efectiva de un tercer agente que es un complejo serotonina creatinina sulfato; (4) un agente tensioactivo no iónico; y (5) un disolvente que es un alcanol inferior. Una composición preferida comprende clorhidrato de metformina, aspirina y complejo serotonina creatinina sulfato para el primer, segundo y tercer agente. Uso de estas composiciones para el tratamiento de síndrome metabólico, enfermedades hiperproliferativas incluyendo cáncer, y otras enfermedades y condiciones.
ARP150103170A 2014-10-01 2015-10-01 Composición farmacéutica que comprende aspirina, metformina y serotonina con agente tensioactivo no iónico AR102147A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462058150P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
AR102147A1 true AR102147A1 (es) 2017-02-08

Family

ID=55631511

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103170A AR102147A1 (es) 2014-10-01 2015-10-01 Composición farmacéutica que comprende aspirina, metformina y serotonina con agente tensioactivo no iónico

Country Status (14)

Country Link
US (1) US20180228818A1 (es)
EP (1) EP3200799A4 (es)
JP (1) JP2017531035A (es)
KR (1) KR20170057451A (es)
CN (1) CN106999496A (es)
AR (1) AR102147A1 (es)
AU (1) AU2015328044A1 (es)
BR (1) BR112017006778A2 (es)
CA (1) CA2961660A1 (es)
MX (1) MX2017004322A (es)
RU (1) RU2017114350A (es)
TW (1) TW201625232A (es)
WO (1) WO2016054365A1 (es)
ZA (1) ZA201702137B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840869A (zh) * 2019-10-15 2020-02-28 四川大学华西第二医院 二甲双胍在子宫内膜异位症药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ZA200609412B (en) * 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
JP2010512230A (ja) * 2006-12-11 2010-04-22 プルーロームド インコーポレイテッド 灌流臓器止血法
CA2675638C (en) * 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
EP2278999A4 (en) * 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
LT2435025T (lt) * 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
EA023396B1 (ru) * 2010-04-01 2016-05-31 Фарманест Аб Термогелеобразующие композиции анестетиков
WO2012135422A2 (en) * 2011-04-01 2012-10-04 University Of Florida Research Foundation, Inc. Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics

Also Published As

Publication number Publication date
US20180228818A1 (en) 2018-08-16
WO2016054365A1 (en) 2016-04-07
ZA201702137B (en) 2018-05-30
EP3200799A1 (en) 2017-08-09
RU2017114350A (ru) 2018-11-05
JP2017531035A (ja) 2017-10-19
CA2961660A1 (en) 2016-04-07
RU2017114350A3 (es) 2019-04-22
TW201625232A (zh) 2016-07-16
BR112017006778A2 (pt) 2018-01-09
CN106999496A (zh) 2017-08-01
EP3200799A4 (en) 2018-05-30
AU2015328044A8 (en) 2017-04-27
AU2015328044A1 (en) 2017-04-20
MX2017004322A (es) 2017-08-28
WO2016054365A8 (en) 2017-04-13
KR20170057451A (ko) 2017-05-24

Similar Documents

Publication Publication Date Title
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2018003429A1 (es) Compuestos novedosos como inhibidores de la autotaxina y composiciones farmacéuticas que los comprenden.
CL2017000287A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
EA202091284A1 (ru) Аналоги инкретина и их применение
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2017002159A2 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2016003329A1 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
DOP2016000007A (es) Pirazolpiridinas sustituidas
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
CL2019003743A1 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes.
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR102147A1 (es) Composición farmacéutica que comprende aspirina, metformina y serotonina con agente tensioactivo no iónico
CU20180110A7 (es) Una composición que comprende pic para el tratamiento del cáncer
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino

Legal Events

Date Code Title Description
FB Suspension of granting procedure